Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialYanjun Zhang, Fengcai Zhu|The Lancet Infectious Diseases|2020Cited by 1.5k
Co-infection with respiratory pathogens among COVID-2019 casesXiaojuan Zhu, Lunbiao Cui, Yiyue Ge et al.|Virus Research|2020Cited by 637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in ChinaYing Chi, Lunbiao Cui, Yiyue Ge et al.|The Journal of Infectious Diseases|2020Cited by 391
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19Yiyue Ge, Jianyang Zeng, Tingzhong Tian et al.|Signal Transduction and Targeted Therapy|2021Cited by 204
Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigationXiaojing Qi, H. Wang, Yishan Qian et al.|BMJ|2013Cited by 184